In the last trading session, 1.16 million shares of the Fate Therapeutics Inc (NASDAQ:FATE) were traded, and its beta was 2.25. Most recently the company’s share price was $1.25, and it changed around -$0.02 or -1.57% from the last close, which brings the market valuation of the company to $142.37M. FATE currently trades at a discount to its 52-week high of $8.83, offering almost -606.4% off that amount. The share price’s 52-week low was $1.04, which indicates that the current value has risen by an impressive 16.8% since then. We note from Fate Therapeutics Inc’s average daily trading volume that its 10-day average is 1.15 million shares, with the 3-month average coming to 3.18 million.
Fate Therapeutics Inc stock received a consensus recommendation rating of Hold, based on a mean score of 2.53. If we narrow it down even further, the data shows that 0 out of 18 analysts rate the stock as a Sell; another 2 rate it as Overweight. Among the rest, 12 recommended FATE as a Hold, whereas 4 deemed it a Buy, and 0 rated it as Underweight. Fate Therapeutics Inc is expected to report earnings per share of -0.43 for the current quarter.
Fate Therapeutics Inc (NASDAQ:FATE) trade information
Instantly FATE has showed a red trend with a performance of -1.57% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 1.4900 on recent trading dayincreased the stock’s daily price by 16.11%. The company’s shares are currently down -24.24% year-to-date, but still down -1.57% over the last five days. On the other hand, Fate Therapeutics Inc (NASDAQ:FATE) is -25.15% down in the 30-day period. We can see from the shorts that 12.7 million shares have been sold at a short interest cover period of 3.69 day(s).
The consensus price target as assigned by Wall Street analysts is $5, which translates to bulls needing to increase their stock price by 75.0% from its current value. Analyst projections state that FATE is forecast to be at a low of $5 and a high of $5.
Fate Therapeutics Inc (FATE) estimates and forecasts
The year-over-year growth rate is expected to be -78.52%, down from the previous year.
Consensus estimates provided by 13 financial analysts predict the company will bring in an average of 1.57M in revenue for the current quarter. 9 analysts expect Fate Therapeutics Inc to make 1.33M in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were 1.68M and 1.93M respectively. Analysts predict that the company’s current quarter sales will drop, forecast at -6.49%. Forecasts for the next quarter put sales growth at -30.89%.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -6.65%. Fate Therapeutics Inc earnings are expected to increase by 0.38% in 2025, but the outlook is positive 2.99% per year for the next five years.
FATE Dividends
Fate Therapeutics Inc’s next quarterly earnings report is expected to be released in March.
Fate Therapeutics Inc (NASDAQ:FATE)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 2.28% of Fate Therapeutics Inc shares, and 100.80% of them are in the hands of institutional investors. The stock currently has a share float of 103.16%. Fate Therapeutics Inc stock is held by 231.0 institutions, with REDMILE GROUP, LLC being the largest institutional investor. By 2024-06-30, it held 13.0252% of the shares, which is about 13.17 million shares worth $43.19 million.
VANGUARD GROUP INC, with 10.4544% or 10.57 million shares worth $34.67 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
